Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Inhibrx BiosciencesINBX | Open-market buy | 09/25–09/28 | 09/28 | 10,000 sh4 trades | $99.88avg. | $998,783.69 | +1.4% | |
Jon Faiz KayyemDirector | Inhibrx BiosciencesINBX | Open-market buy | 09/23 | 09/23 | 5,000 sh | $100.00 | $500,000 | +1.2% |
Inhibrx BiosciencesINBX | Open-market sale | 25/10/07 | 25/10/09 | 350,000 sh3 trades | $32.25avg. | $11,287,500 | −77.3% | |
Inhibrx BiosciencesINBX | Open-market sale | 25/10/07 | 25/10/09 | 350,000 sh3 trades | $32.25avg. | $11,287,500 | −77.3% | |
Inhibrx BiosciencesINBX | Open-market sale | 25/10/07 | 25/10/09 | 350,000 sh3 trades | $32.25avg. | $11,287,500 | −77.3% | |
Inhibrx BiosciencesINBX | Open-market sale | 25/10/07 | 25/10/09 | 350,000 sh3 trades | $32.25avg. | $11,287,500 | −77.3% | |
Inhibrx BiosciencesINBX | Open-market sale | 25/10/07 | 25/10/09 | 350,000 sh3 trades | $32.25avg. | $11,287,500 | −77.3% | |
Inhibrx BiosciencesINBX | Open-market sale | 25/10/07 | 25/10/09 | 350,000 sh3 trades | $32.25avg. | $11,287,500 | −77.3% | |
Inhibrx BiosciencesINBX | Open-market sale | 25/10/07 | 25/10/09 | 350,000 sh3 trades | $32.25avg. | $11,287,500 | −77.3% | |
Inhibrx BiosciencesINBX | Open-market sale | 25/10/07 | 25/10/09 | 350,000 sh3 trades | $32.25avg. | $11,287,500 | −77.3% | |
Inhibrx BiosciencesINBX | Open-market buy | 24/11/19–24/11/20 | 24/11/22 | 107,186 sh4 trades | $14.22avg. | $1,523,756.78 | No record | |
Kristiina Md VuoriDirector | Inhibrx BiosciencesINBX | Open-market buy | 24/10/03 | 24/10/07 | 6,667 sh | $15.00 | $100,005 | +48.4% |
Inhibrx BiosciencesINBX | Open-market buy | 24/09/12–24/09/16 | 24/09/16 | 40,000 sh2 trades | $15.73avg. | $629,116.96 | +6.0% | |
Inhibrx BiosciencesINBX | Open-market buy | 24/09/10–24/09/11 | 24/09/12 | 6,636 sh2 trades | $15.07avg. | $99,991.99 | +92.9% | |
Inhibrx BiosciencesINBX | Open-market buy | 24/09/06–24/09/10 | 24/09/10 | 44,000 sh3 trades | $15.25avg. | $671,150 | +7.1% | |
Inhibrx BiosciencesINBX | Open-market buy | 24/08/29–24/09/03 | 24/09/03 | 40,000 sh4 trades | $14.92avg. | $596,762.8 | +32.0% | |
Kristiina Md VuoriDirector | Inhibrx BiosciencesINBX | Open-market buy | 24/08/29 | 24/09/03 | 7,140 sh | $14.00 | $99,960 | No record |
Kimberly ManhardDirector | Inhibrx BiosciencesINBX | Open-market buy | 24/08/28 | 24/08/30 | 10,000 sh | $13.98 | $139,800 | No record |
Inhibrx BiosciencesINBX | Open-market buy | 24/08/22–24/08/23 | 24/08/26 | 75,000 sh2 trades | $13.83avg. | $1,037,328.16 | +50.1% | |
Inhibrx BiosciencesINBX | Open-market buy | 24/08/20–24/08/21 | 24/08/22 | 40,000 sh2 trades | $12.96avg. | $518,282.2 | +269.1% |